👨 Testosterone Therapy Cardiovascular Risk Simulator

Historical FDA Warning on Testosterone and Cardiovascular Risk

Early observational signals prompted regulatory caution on TRT.

• 2015: FDA warning added (Label update on CV risk)
• 2013–2014: Trigger study (VA cohort & JAMA studies)
• Disputed: Risk signal (Methodology criticized)
• All TRT products: Label scope (Class-wide caution)

Regulatory background

Placeholder: brief history of the FDA safety communication on testosterone.

Studies that triggered concern

Placeholder: short note on the observational studies behind the warning.

Placeholder highlight: warning prompted more rigorous trials.

Conflicting Trial Evidence — the TRAVERSE Randomized Trial

TRAVERSE is the largest randomized CV safety trial of testosterone.

• TRAVERSE: Trial name (Published 2023, NEJM)
• ~5,200: Participants (Men with hypogonadism)
• Non-inferior: Primary outcome (MACE vs placebo)
• ~22 months: Duration (Mean follow-up)

Trial design summary

Placeholder: short description of TRAVERSE randomized design.

Reconciling earlier signals

Placeholder: short note on why earlier studies differed.

Placeholder highlight: no overall MACE increase found.

Hematocrit Elevation and Thrombosis Risk During Therapy

Testosterone stimulates erythropoiesis, raising hematocrit and viscosity.

• ~5–15%: Erythrocytosis risk (Of treated patients)
• 54%: Hct safety ceiling (Common threshold for pause)
• 3–12 months: Onset (Typical time to elevation)
• EPO ↑: Mechanism (Erythropoietin stimulation)

Mechanism of erythrocytosis

Placeholder: short note on testosterone-driven red cell increase.

Clot risk implications

Placeholder: short note on viscosity and thrombosis link.

Placeholder highlight: hematocrit is the key modifiable marker.

Baseline Cardiovascular Risk Stratification Before Therapy

Pre-therapy screening identifies patients needing closer monitoring.

• ASCVD score: Screening tools (Plus history review)
• Prior MI/stroke: High-risk flags (Recent CV events)
• Recommended: Shared decision (Patient counseling step)
• Uncontrolled CVD: Contraindication (Relative caution zone)

Stratification approach

Placeholder: short note on baseline risk categorization.

Shared decision-making

Placeholder: short note on counseling higher-risk candidates.

Placeholder highlight: individualized risk-benefit discussion matters.

Monitoring Protocol During Ongoing Testosterone Therapy

Scheduled labs track hematocrit, lipids, and CV symptoms over time.

• 3, 6, 12 mo: Hct check (Then annually)
• Annual: Lipid panel (Or as indicated)
• Hct >54%: Action threshold (Dose adjust / pause)
• Ongoing: Follow-up (Duration of therapy)

Monitoring schedule

Placeholder: short note on lab check cadence during TRT.

Response to abnormal values

Placeholder: short note on dose reduction or therapeutic phlebotomy.

Placeholder highlight: routine monitoring reduces avoidable risk.